当前位置: X-MOL 学术Blood › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Blood ( IF 20.3 ) Pub Date : 2022-01-27 , DOI: 10.1182/blood.2021012589
Guillermo Garcia-Manero 1 , Ghulam J Mufti 2 , Pierre Fenaux 3 , Rena Buckstein 4 , Valeria Santini 5 , María Díez-Campelo 6 , Carlo Finelli 7 , Osman Ilhan 8 , Mikkael A Sekeres 9 , Amer M Zeidan 10 , Rodrigo Ito 11 , Jennie Zhang 11 , Anita Rampersad 11 , Daniel Sinsimer 11 , Jay T Backstrom 12 , Uwe Platzbecker 13 , Rami S Komrokji 14
Affiliation  



中文翻译:

在低风险 MDS 中,中性粒细胞和血小板随着 luspatercept 增加:MEDALIST 试验的次要终点。

更新日期:2021-11-10
down
wechat
bug